In the early stages of drug development, we adhere to the principle of "quick win, fast fail." During the early discovery phase, we strive to mitigate potential risks as much as possible, such as specificity risks, efficacy and toxicology risks, stability risks, and process development risks. By conducting more in-depth research, enhancing exploratory depth, and performing thorough analysis and prediction at this stage, we aim to avoid greater wastage of resources and time in later development phases.

AceMab collaborates closely with Taichu group —TaiChu Bio (Pre-Clinical Research CRO ) and Tarlead Biologics (Biologics Development and Manufacturing CDMO ) —to thoroughly consider risks early on and conduct comprehensive validation work. Ultimately, we are committed to advancing the most promising molecules to the market, contributing to human health and well-being.

AceMab places exceptional emphasis on project management, with all team members—from the founders to the project managers—holding professional PMP certification issued by a UK-based project management training institution. Dr. Li Jianliang, the founder, believes that the most easily overlooked cost for enterprises is project management cost, and the most easily overlooked benefit is management efficiency. Therefore, it is essential for AceMab’s internal scientists and project management team to receive professional training in management. Throughout project execution, we welcome valuable feedback from our clients, as it enables us to continuously improve and advance. This has always been our original intention and service commitment.